In Japan, the rate of pulmonary nontuberculous mycobacteriosis (NTM) (atypical mycobacterial diseases) in the total pulmonary mycobacteriosis is continously increasing, in 1994
The first Japanese case ofM. kansasii was reported in 1963 by Kawabe et al (2) . Prior to 1980, the rate of this infection in total NTMwas only 6% or7%, and the cases were limitedto the Tokyo and Kanagawa areas, but in 1980 the rate increased to over 20% and this infection began to appear in throughout Japan (3) . Since 1980, the rate of M. kansasii cases has increased gradually; it reached 27.5% in 1985 and has maintained almost the same level since then (1, 4) . The reason for the change in epidemiological status of infection ofM. kansasii is unclear, but in part it depends on the ecological changes in Japan, and in part on the development of methods for identification of the species of mycobacteria.
See also p 298.
The sex and age distribution of the cases ofM. kansasii differ from those of M. aviumcomplex; male/female ratio of the former is 37/1 and the average age is 46.9 years old, while they are 54/41 and 66.4 years old in the latter (4) . This may indicate a morestrong virulence ofM. kansasii than M. avium complex. NTMfrequently affects cases with previous lung disease, but M. kansasii affects more cases without previous diseases than M. aviumcomplexand this also indicate a difference in virulence betweenthese species. The clinical course of the pulmonary disease due to M. kansasii was relatively poor, from the first report by Buhler and Pollak (5) in 1953 to the '60's reportofJohansonandNicholson (6) , due to the low susceptibility of antituberculous drugs used for this bacteria at that time, but the development of rifampicin (RFP) and ethambutol (EB) changed the clinical course of this infection dramatically. Ahn et al (7) reported that in all 40 previously untreated pulmonary M. kansasii patients treated for 1 2 months with daily chemotherapy of isoniazid, RFP, EB and with streptomycin twice weekly for the first 3 months, their sputum converted to negative and relapse occurred in only one case 6 monthsafter treatment. They considered that this regimen is sufficient for the treatment of this infection. The British Thoracic Society (8) recommendednine months of treatment with RFPand EBas an efficient regimen for this infection, by a large, prospective, multicenter study. These excellent results were dependent on the high susceptibility of this bacilli to RFP and EB, and the therapeutic effects of this regimen was ineffective in the resistant cases for RFPand EB, such as the case reported by Yamada et al (9) , and the development of drugs for RFP-and EBresistant cases is necessary, although quinolons and macrolides has been studied as possible drugs (10). Fortunately, the rate of primary resistant cases for RFP is low in wild strains, Wallance et al ( 1 1 ) reported that the rate ofRFPresistant bacilli was only 4% of464 isolates recovered in Texas between 1989 and 1992, and 90% of them had previously received RFP. In Japan, primary resistant cases for RFP are also rare (12). The possibility of the rapid decrease of the susceptibility of this bacilli for RFPor EBseemed low, since water was regarded as the most probable factor of transmission of M. kansasii (13), and the possibility of human to human infection seemed low even in patients with acquired immunodeficiency syndrome.
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